SynCardia Forms European Entity to Address Growing Demand for
World’s Only Approved Total Artificial Heart
18 New European Hospitals Have Enrolled in SynCardia’s Certification Program to Implant the Total Artificial Heart during the Last 15 Months.
SynCardia Systems, Inc., manufacturer of the world’s only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today it has formed SynCardia Systems Europe GmbH in Bad Oeynhausen, Germany, to address growing demand for the SynCardia temporary Total Artificial Heart in
the European market. SynCardia GmbH will be led by Managing Directors Oliver Voigt, PhD and Markus Leinberger, RN.
“With a dedicated European clinical support team and sales force, SynCardia GmbH will be able to provide hospitals with better customer service and support while continuing to expand current markets and
open new ones,” said Mr. Leinberger.
During the past 15 months, 18 new European hospitals have enrolled in SynCardia’s four-phase Certification Program to implant the Total Artificial Heart, bringing the total number of SynCardia customers in Europe to 43 hospitals… read more at SynCardia.com